NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.82 -0.03 (-0.44 %)
(As of 05/22/2019 06:36 AM ET)
Previous Close$6.85
Today's Range$6.77 - $7.17
52-Week Range$5.58 - $27.06
Volume47,193 shs
Average Volume105,045 shs
Market Capitalization$143.34 million
P/E RatioN/A
Dividend YieldN/A
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLMD



Sales & Book Value

Annual Sales$2.04 million
Book Value$4.04 per share


Net Income$-9,860,000.00
Net Margins-423.62%


Market Cap$143.34 million
Next Earnings Date8/1/2019 (Estimated)

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.02. Galmed Pharmaceuticals had a negative net margin of 423.62% and a negative return on equity of 12.23%. View Galmed Pharmaceuticals' Earnings History.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Galmed Pharmaceuticals.

What price target have analysts set for GLMD?

7 Wall Street analysts have issued 12-month price targets for Galmed Pharmaceuticals' stock. Their predictions range from $20.00 to $59.00. On average, they expect Galmed Pharmaceuticals' stock price to reach $35.75 in the next twelve months. This suggests a possible upside of 424.2% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.

What is the consensus analysts' recommendation for Galmed Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.

What are Wall Street analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value S/O as of Aramchol – NASH (U.S.) 55.0% $20.05 $36.43 Shares outstanding 21,113 Aramchol – NASH (EU) 40.0% $5.33 $13.31 Current share price $7.11 Discount rate 14.0% Cash beyond 12 months $2.58 $2.58." (5/8/2019)
  • 2. Maxim Group analysts commented, "Galmed reported 1Q19 with a net loss of ($3.5M) and ended the period with $86.6M in cash." (5/7/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $59 12-month PT on Galmed Pharmaceuticals following earnings from 4Q18/2018. The company announced plans to have an end-of-Phase 2b meeting with the FDA during March, with the goal of initiating the Phase 3 ARMOR study in late-2Q19/early-3Q19. Minutes from this meeting and finalized Phase 3 trial design plans could be important data points in 2019. Additionally, Galmed will present a poster on Aramchol improvement in liver glucose homeostasis in NASH at EASL on 4/13 (link)." (3/13/2019)
  • 4. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (2/28/2019)

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Media headlines about GLMD stock have trended somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Rite Aid (RAD), Opko Health (OPK), Micron Technology (MU), Verastem (VSTM), Conatus Pharmaceuticals (CNAT), Exelixis (EXEL), Immunomedics (IMMU), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP) and Portola Pharmaceuticals (PTLA).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:
  • Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
  • Mr. Yohai Stenzler, CFO & Controller (Age 36)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 34)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 49)

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Ibex Investors LLC (3.14%), First Midwest Bank Trust Division (0.85%), ARK Investment Management LLC (0.26%), JPMorgan Chase & Co. (0.18%), Delek Group Ltd. (0.10%) and Morgan Stanley (0.03%).

Which institutional investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Morgan Stanley.

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was purchased by a variety of institutional investors in the last quarter, including Ibex Investors LLC, JPMorgan Chase & Co., Delek Group Ltd. and ARK Investment Management LLC.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $6.82.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $143.34 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.

MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel